drugset / Trial / NCT00187070
Large Cell Lymphoma Pilot Study III
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The main purpose of this study is to find out if it is feasible to deliver a multi-agent chemotherapy regimen which features a shorter, more intensive, immunophenotype-directed approach, and includes an intensification phase with hematopoietic stem cell support for children with large cell lymphoma
Timeline
- Start
- 1997-12
- Primary completion
- 2001-07
- Completion
- 2001-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Cyclophosphamide | Other / unclassified | 500 mg/m2 | — |
| Subject | Cyclophosphamide | Other / unclassified | 1000 mg/m2 | — |
| Subject | Cytarabine | Small molecule | 2000 mg/m2 | — |
| Subject | Dexamethasone | Small molecule | 40 mg/m2 | Intravenous |
| Subject | Doxorubicin | Other / unclassified | 60 mg/m2 | Intravenous |
| Subject | Etoposide | Small molecule | 200 mg/m2 | — |
| Subject | Ifosfamide | Small molecule | 2000 mg/m2 | — |
| Subject | Methotrexate | Small molecule | 5000 mg/m2 | Intravenous |
| Subject | Methotrexate | Small molecule | 8000 mg/m2 | Intravenous |
| Subject | Prednisone | Other / unclassified | 60 mg/m2 | — |
| Subject | Vinblastine | Small molecule | 6 mg/m2 | Intravenous |
| Subject | Vincristine | Small molecule | 2 mg/m2 | — |
| Background | trimethoprim-sulfamethoxazole | Unknown | — | — |